A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration

Simple item page
dc.contributor.authorRitchie, C.
dc.contributor.authorChiu, E.
dc.contributor.authorHarrigan, S.
dc.contributor.authorMacfarlane, S.
dc.contributor.authorMastwyk, M.
dc.contributor.authorHalliday, G.
dc.contributor.authorHustig, H.
dc.contributor.authorHall, K.
dc.contributor.authorHassett, A.
dc.contributor.authorO'Connor, D.
dc.contributor.authorOpie, J.
dc.contributor.authorNagalingam, V.
dc.contributor.authorSnowdon, J.
dc.contributor.authorAmes, D.
dc.date.issued2006
dc.description.abstractBackground: Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effects. Aims: To determine whether either olanzapine or risperidone was superior in terms of efficacy or side effects when treating schizophrenia in late life. Methods: Psychiatric symptoms, side effects and quality of life were rated every six weeks for 24 weeks of open label comparative treatment using standard measures. Group differences were examined using analysis of covariance and within-group changes over time were assessed using paired t-tests. Results: There were 34 olanzapine and 32 risperidone patients who entered the study, but intention to treat data was only available for 61 of the 66 patients. There were no clinical or demographic differences between the groups. Parkinsonism, positive and negative symptoms of schizophrenia improved in both groups both from baseline switch to olanzapine or risperidone and during the six month follow-up after completion of crossover. No significant differences were seen between groups on most measures. However, patients treated with olanzapine showed a significantly greater improvement in quality of life from baseline compared to risperidone patients. Conclusions: Both drugs were well tolerated and their use was associated with fewer symptoms of schizophrenia and less adverse effects than were seen when the patients were taking a typical antipsychotic at baseline. Olanzapine appears to have particular benefit with regard to quality of life.
dc.description.statementofresponsibilityC. W. Ritchie, E. Chiu, S. Harrigan, S. Macfarlane, M. Mastwyk, G. Halliday, H. Hustig, K. Hall, A. Hassett, D. W. O'Connor, J. Opie, V. Nagalingam, J. Snowdon and D. Ames
dc.identifier.citationInternational Journal of Geriatric Psychiatry, 2006; 21(2):171-179
dc.identifier.doi10.1002/gps.1446
dc.identifier.issn0885-6230
dc.identifier.issn1099-1166
dc.identifier.urihttp://hdl.handle.net/2440/23304
dc.language.isoen
dc.publisherJohn Wiley & Sons Ltd
dc.rightsCopyright © 2006 John Wiley & Sons, Ltd
dc.source.urihttps://doi.org/10.1002/gps.1446
dc.subjectschizophrenia
dc.subjectelderly
dc.subjectolanzapine
dc.subjectrisperidone
dc.subjectclinical trial
dc.subjectquality of life
dc.titleA comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Psychiatry publications